SecBot SecBot
SECBOTREPLAY Home › Report › PVLA

PVLA · Palvella Therapeutics appointed Matthew Pauls as a Class I director,…

PALVELLA THERAPEUTICS, INC. · 8-K filed Jun 30, 2026 at 07:36 ET

At the news

NEUTRALIMPACT 2/10

8-K filed Jun 30, 2026 at 07:36 ET

Palvella Therapeutics appointed Matthew Pauls as a Class I director, expanding the board from seven to eight members. Mr. Pauls is the CEO of Savara, Inc. and brings rare disease and commercialization experience, including a prior board role at Soleno Therapeutics through its $2.9B acquisition. This is a routine board appointment with no material financial impact.

  • Board expanded from 7 to 8 members on June 29, 2026
  • Matthew Pauls appointed as Class I director, term expiring at 2027 Annual Meeting
  • Mr. Pauls is CEO of Savara, Inc. (NASDAQ: SVRA)
  • Granted option to purchase 6,000 shares vesting monthly over 36 months

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access